EZH2 and cancer: Early observations demonstrated that EZH2 was overexpressed in prostate tumours and played a role in the progression of this cancer type.101 Since then, many reports have shown that other PRC2 factors are subject to deletions, mutations, translocations and/or dysregulation in different cancer types.